Browse EX-10 agreements

AMENDMENT NO. 1

TO THE

CABALETTA BIO, INC. 2025 INDUCEMENT PLAN

WHEREAS, Cabaletta Bio, Inc. (the “Company”) maintains the Cabaletta Bio, Inc. 2025 Inducement Plan (the “Inducement Plan”), which was previously adopted by the Board of Directors of the Company (the “Board”);

WHEREAS, the Board desires to amend the Inducement Plan to increase the number of shares available for issuance under the Inducement Plan;

WHEREAS, Section 16 of the Inducement Plan provides that the Board may amend the Inducement Plan at any time, subject to certain conditions set forth therein; and

NOW, THEREFORE:

1.

Section 3(a) of the Inducement Plan is hereby amended by deleting “275,000” where it appears in the first sentence thereof and replacing it with “1,275,000.”

2.

This Amendment to the Inducement Plan shall become effective upon the date that it is approved by the Board.

3.

Except as set forth above, all other provisions of the Inducement Plan shall remain

unchanged.

IN WITNESS WHEREOF, this Amendment No. 1 to the Inducement Plan has been adopted by the Board of Directors of the Company this 3rd day of April 2026.

---

Certain confidential information contained in this document, marked by [***], has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential.

S15-479:IG	EXCLUSIVE (EQUITY) AGREEMENT	** **

Execution Copy

EXCLUSIVE (EQUITY) AGREEMENT

This Exclusive (Equity) Agreement (“Agreement”) is entered into between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (‘‘Stanford”), an institution of higher education having powers under the laws of the State of California, and Abeona Therapeutics Inc. (“Abeona”), a Delaware corporation, having a principal place of business at 1325 Avenue of the Americas, 27th Floor, New York, NY 10019. is effective on the 3rd day of August, 2016 (“Effective Date”).

1.	BACKGROUND

Stanford has an assignment of an invention entitled ‘“Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa using Genetically Corrected Autologous Keratinocytes,” described in Stanford Docket S15-479, invented by Paul Khavari, Alfred Lane. Ngon Nguyen, Zurab Siprashvilli, and Jean Tang, employees of Stanford, and by M. Peter Marinkovich, an employee of Stanford and the United States Department of Veterans Affairs (“VA”).

…

SIXTH AMENDMENT TO

SECOND AMENDED AND RESTATED CREDIT AGREEMENT

THIS SIXTH AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) is entered into as of August 12, 2026 (the “Effective Date”), by and among WELLS FARGO CAPITAL FINANCE, LLC, a Delaware limited liability company, as a joint lead arranger and administrative agent (the “Agent”) for the Lenders (as defined in the Credit Agreement referred to below), the Lenders party hereto, WABASH NATIONAL CORPORATION, a Delaware corporation (“Wabash”), certain Subsidiaries of Wabash designated on the signature pages hereto as borrowers (together with Wabash, such Subsidiaries are collectively referred as the “Borrowers”) and certain Subsidiaries of Wabash designated on the signature pages hereto as guarantors. Capitalized terms not otherwise defined herein have the definitions provided therefor in the Credit Agreement (as hereinafter defined).

WHEREAS, Borrowers, Agent, and Lenders are parties to that certain Second Amended and Restated Credit Agreement dated as of December 21, 2018 (as amended, restated, modified or supplemented from time to time, the “Credit Agreement”);

WHEREAS, Borrowers have requested that Agent and Lenders agree to amend the Credit Agreement in the manner specified in this Amendment;

WHEREAS, New Lender (as defined below) has agreed to join the Credit Agreement as a Lender; and

WHEREAS, Agent and Lenders have agreed to Borrowers’ requests, on the terms and subject to the conditions set forth herein.

…

PELTHOS THERAPEUTICS INC.

2023 Equity Incentive Plan

Performance Stock Unit Agreement

This Performance Stock Unit Agreement and the associated grant award information (the “Customizing Information”), which Customizing Information is provided in written form (the “Performance Stock Unit Schedule”) or is available in electronic form from the record keeper for the Pelthos Therapeutics Inc. 2023 Equity Incentive Plan, as amended and restated and in effect from time to time (the “Plan”), made as of the date shown as the “Grant Date” in the Customizing Information (the “Grant Date”) by and between Pelthos Therapeutics Inc., a Nevada corporation (the “Company”), and the individual identified in the Customizing Information (the “Recipient”). This instrument and the Customizing Information are collectively referred to as the “Performance Stock Unit Agreement.”

WITNESSETH THAT:

WHEREAS, the Company has instituted the Plan; and

WHEREAS, the Board or the Compensation Committee (the “Committee”) has authorized the grant of performance stock units with respect to the Company’s Common Stock (“Stock”) upon the terms and conditions set forth below and pursuant to the Plan, a copy of which is incorporated herein; and

…

ZENAS BIOPHARMA, INC.

2024 EMPLOYEE STOCK PURCHASE PLAN**
**(AMENDED AND RESTATED ON MAY 18, 2026)

1.	Defined Terms

Exhibit A, which is incorporated by reference, defines the terms used in this Plan and sets forth certain operational rules related to those terms.

2.	Purpose of Plan

(a)Purpose. This Plan is intended to enable Eligible Employees to purchase shares of Stock in offerings under this Plan, and thereby acquire an interest in the Company. This Plan is intended to be exempt from the application and requirements of Section 409A of the Code, and is to be construed accordingly.

(b)Qualified and Non-Qualified Offerings Permitted. This Plan includes two components: a 423 Component and a Non-423 Component. The Company intends (but makes no undertaking or representation to maintain) the 423 Component to qualify as an “employee stock purchase plan” under Section 423. The provisions of the 423 Component, accordingly, will be construed in a manner that is consistent with the requirements of Section 423. In addition, this Plan authorizes grants of Options under the Non-423 Component that do not meet the requirements of Section 423. Except as otherwise provided in this Plan or as the Administrator determines, the Non-423 Component will operate and be administered in the same manner as the 423 Component. Eligible Employees will be able to participate in either the 423 Component or the Non-423

…

INDEMNIFICATION AGREEMENT

THIS AGREEMENT is made this _______ day of __________, 20___, by and between BK Technologies Corporation, a Nevada corporation (the “Corporation”), and _______________________ (the “Director and/or Officer”).

WHEREAS, the Director and/or Officer has agreed to serve, or continue to serve, as a director and/or officer of the Corporation or as a director, officer, trustee, manager, participating member and/or in any other similar capacity of an Other Entity (as defined below) (any one or more of which capacities constitute an “Indemnified Capacity”),** **providing that adequate liability insurance, indemnification or a combination thereof is, and will continue to be, provided;

WHEREAS, the Corporation, in order to induce the Director and/or Officer to serve or continue to serve the Corporation and/or an Other Entity, has agreed to execute this Agreement to evidence the indemnification of the Director and/or Officer to the fullest extent permitted by law; and

WHEREAS, as a result of such indemnification, the Director and/or Officer has agreed to serve or to continue to serve in an Indemnified Capacity;

NOW THEREFORE, in consideration of the promises, conditions, representations and warranties set forth herein, including the Director and/or Officer’s service or continued service to the Corporation and/or Other Entity, the Corporation and the Director and/or Officer hereby agree as follows:

…

LEASE AGREEMENT

THIS LEASE AGREEMENT (this “Agreement”) dated this 11th day of May, 2026 (the “Effective Date”), is by and between Notes Live Foundation, a Colorado non-profit corporation d/b/a Venu Arts & Culture Foundation (“Foundation”) and Sunset Operations, LLC, a Colorado limited liability company (“Sunset”, collectively with Foundation, the “Landlords”) and AEG Presents – Rocky Mountains, LLC, a Delaware limited liability company (“Tenant”).

RECITALS

WHEREAS, the Foundation was organized and is operated exclusively for charitable and educational purposes within the meaning of Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the “Code”), and specifically the promotion of arts and culture through free community concerts conducted, grants made, and educational programs delivered, within the State of Colorado. In furtherance of the foregoing, the Foundation intends to (i) host and produce free community concerts at the Venue (defined below), or other local venues, featuring local, volunteer and nascent performing artists in and around the City of Colorado Springs (“City”), Colorado, and (ii) partner, through educational programs and grantmaking activities, with local educational, arts, and vocational institutions that are exempt under Section 501(c)(3) of the Code to support existing efforts to further arts and culture within the State of Colorado.

WHEREAS, Sunset is a Colorado limited liability company formed by the Venue’s (defined below) owners to oversee certain operations at the Venue.

…

VENUE LEASE AGREEMENT

** **

THIS VENUE LEASE AGREEMENT (“Lease”) is made and entered into as of May 11, 2026 (the “Effective Date”) by and between Sunset Amphitheater, LLC a Colorado limited liability company whose address is 1755 Telstar Drive, Suite 501, Colorado Springs, CO 80920, herein designated as the “Landlord,” and Notes Live Foundation, a Colorado non-profit corporation, whose address 1755 Telstar Drive, Suite 501, Colorado Springs, CO 80920 d/b/a Venu Arts & Culture Foundation (“Foundation”), and Sunset Operations, LLC, a Colorado limited liability company, whose address is 1755 Telstar Drive, Suite 501, Colorado Springs, CO 80920 (“Sunset,” collectively with Foundation, the “Tenants”).

WITNESSETH:

** **

In consideration of the rent to be paid and the covenants to be performed by Tenants hereunder, Landlord does hereby lease and demise to Tenants, and Tenants do hereby lease and take from Landlord, the Premises described below, upon the following terms and conditions:

…

Execution Version

SECOND AMENDMENT TO TERM LOAN AND SECURITY AGREEMENT

This SECOND AMENDMENT TO TERM LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of August 13, 2026, with a retroactive effective date as of March 17, 2026, by and among SOUTHLAND HOLDINGS LLC, a Texas limited liability company, as a Borrower, SOUTHLAND HOLDINGS, INC., a Delaware corporation, as a Guarantor, each other Guarantor party hereto, the lenders identified on the signature pages hereof (each such lender, together with its successors and permitted assigns, is referred to hereinafter as a “Lender”) and Alana Porrazzo, Esq. of Jennings, Haug, Kelcher, Mcleod Waterfall LLP, in her capacity as the Trustee of the Southland Collateral Trust, as agent for the Lenders (in such capacity, the “Agent”).

WITNESSETH:

WHEREAS, the Borrowers, the Guarantors, the Lenders and Agent are parties to that certain Term Loan and Security Agreement, dated as of September 30, 2024, as amended by that certain First Amendment to Term Loan and Security Agreement, dated as of March 3, 2025 and as modified by that certain Assignment and Assumption, dated March 17, 2026 (as so amended and modified, the “Existing Loan Agreement”; the Existing Loan Agreement as amended hereby is referred to herein as the “Loan Agreement”); and

WHEREAS, the Borrowers have requested that the Agent and the Lenders provide for certain modifications to the Existing Loan Agreement, and the Agent and the Lenders are willing to do so upon the terms and conditions set forth herein.

…

** **

Execution Version

Certain confidential portions have been redacted from this exhibit because they are both (i) not material and (ii) is the type that the company treats as private or confidential. Information that has been omitted had been identified in this document with a placeholder identified by the mark “[redacted]”.

FINANCIAL ASSISTANCE AGREEMENT

This Financial Assistance Agreement (the “Agreement”) is entered into as of August 13, 2026 (the “Execution Date”), with a retroactive effective date as of October 1, 2025 (“Effective Date”), by and among Berkshire Hathaway Specialty Insurance Company (“Berkshire”), Zurich American Insurance Company (“Zurich”), Hartford Fire Insurance Company, Euler Hermes North America, Markel Insurance Company (“Markel”), Western Surety Company, Federal Insurance Company (collectively referred to as “Sureties” and each as “Surety”), Southland Holdings, LLC (“Southland”), Southland Holdings, Inc. (the “Issuer”), Southland RE Properties LLC, Southland Contracting, Inc., Heritage Materials, LLC, Southland Mole of Canada, Ltd., Johnson Bros. Corporation, a Southland Company, Oscar Renda Contracting, Inc., Oscar Renda Contracting of Canada, Inc., Renda Pacific LLC, Mole Constructors, Inc., American Bridge Holding Company, American Bridge Company, American Bridge Manufacturing Company, American Dock & Transfer Company, American Bridge International Corporation, American Bridge Canada Company, Renda-Jbros Joint Venture, Southland Renda JV, Southland Mole JV

…

July 24, 2026

Jason O’Byrne

EMAIL/DOCUSIGN

Re: Employment Agreement

Dear Jason,

Olema Pharmaceuticals, Inc. (the “Company”) is pleased to offer you employment as its Chief Financial Officer, pursuant to the terms of this offer letter agreement (the “Agreement”).

1.

Position; Duties. You will have overall responsibility for leading the Company’s finance organization and overseeing financial strategy, capital allocation, financial operations, corporate communications, investor relations, and related corporate functions, reporting directly to the Company’s Chief Executive Officer, working out of the Company’s San Francisco area office or at other locations as mutually agreed. You agree to devote your best efforts and full business time, skill and attention to the performance of your duties. You are also required to adhere to the general employment policies and practices of the Company that may be in effect from time to time, except that when the terms of this Agreement conflict with the Company’s general employment policies or practices, this Agreement will control. The Company may change your position, duties, work location and, on a prospective basis only, compensation from time to time in its discretion, subject to the terms and conditions set forth herein. Your anticipated start date will be August 11, 2026 (such actual date of your commencement of employment shall be referred to herein as the “Start Date”).

2.

…

EXECUTION VERSION

EIGHTH AMENDMENT TO THE

RECEIVABLES FINANCING AGREEMENT

This EIGHTH AMENDMENT TO THE RECEIVABLES FINANCING AGREEMENT (this “Amendment”), dated as of June 25, 2026, is entered into by and among the following parties:

(i)

AVEANNA SPV I, LLC, as Borrower;

(ii)

AVEANNA HEALTHCARE LLC, as initial Servicer; and

(iii)

PNC BANK, NATIONAL ASSOCIATION (“PNC”), as Administrative Agent and a Lender.

Capitalized terms used but not otherwise defined herein (including such terms used above) have the respective meanings assigned thereto in the Receivables Financing Agreement described below.

BACKGROUND

A.

The parties hereto are parties to the Receivables Financing Agreement, dated as of November 12, 2021 (as amended, restated, supplemented or otherwise modified through the date hereof, the “Receivables Financing Agreement”).

B.

The parties hereto desire to amend the Receivables Financing Agreement as set forth herein.

NOW, THEREFORE, with the intention of being legally bound hereby, and in consideration of the mutual undertakings expressed herein, each party to this Amendment hereby agrees as follows:

SECTION 2.

Amendments to the Receivables Financing Agreement.The Receivables Financing Agreement is hereby amended as shown on the marked pages of the Receivables Financing Agreement attached hereto as Exhibit A.

SECTION 3.

Representations and Warranties of the Borrower and Servicer. The Borrower and the Servicer hereby represent and warrant to each of the parties hereto as of the date hereof as follows:

(a)

…